SecBot SecBot
PRESS-RELEASE ·Filed Apr 27, 2026

SION

Sionna Therapeutics, Inc.
MIXED
Impact 6/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ◆ Mixed

Position ahead of summer 2026 data readout, which could validate NBD1 stabilization as a new mechanism in CF. Monitor for signs of clinical differentiation, especially in sweat chloride reduction beyond Trikafta alone. Given recent insider selling of $50.8M, assess management conviction at data release.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$39.21
T+0 close · Apr 27, 2026 · via day close
Latest settled
+14.84%
T+60 · $45.03
Vs SPY
+10.07%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $39.21entry
  2. T+1 · 7mo ago +0.97%α +1.45% · $39.59
  3. T+5 · 7mo ago +3.16%α +2.76% · $40.45
  4. T+20 · 6mo ago +9.36%α +4.40% · $42.88
  5. T+60 · 4mo ago +14.84%α +10.07% · $45.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sionna Therapeutics announced completion of patient enrollment in its Phase 2a PreciSION CF trial evaluating SION-719, a first-in-class NBD1 stabilizer, in cystic fibrosis patients on Trikafta. Topline data is expected in summer 2026, marking a key clinical catalyst for the company's novel CFTR-targeting approach.

Key Facts

  • Completed enrollment in Phase 2a PreciSION CF trial for SION-719, a first-in-class NBD1 stabilizer.
  • Trial evaluates SION-719 added to Trikafta in F508del-homozygous CF patients using a crossover design.
  • Primary endpoints include safety, pharmacokinetics, and change in sweat chloride levels (a biomarker of CFTR function).
  • Topline data expected in summer 2026, representing a near-term clinical readout.
  • Trial conducted across sites in the CF Foundation’s Therapeutics Development Network.

Financial Impact

No direct financial impact disclosed; clinical milestone de-risking potential ahead of data readout.

cash runwayR&D spendmarket valuation

Risk Factors

  • Clinical failure risk: No guarantee that SION-719 will show meaningful improvement in sweat chloride or safety.
  • High valuation sensitivity: With $1.7B market cap and no approved products, stock is highly dependent on clinical execution.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3281460

Track record

22 reports on SION

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +89.29% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $3.70 Now $3.12 −15.68% settles Nov 17
  2. Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $3.57 to $3.12 Now $3.12 −12.61% ▼ −12.61% −10.91% vs SPY
  3. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $3.65 to $3.70 Now $3.12 −14.52% ▲ +1.37% +1.96% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $6.02 to $5.15 Now $3.12 −48.17% ▼ −14.45% −13.26% vs SPY
  5. Sep 21, 20268w ago SC 13D/A Bearish 7/10 Entry $6.02 to $5.15 Now $3.12 +48.17% ▲ +14.45% +13.26% vs SPY
  6. Sep 17, 20268w ago 144 Bearish 5/10 Entry $5.96 to $5.23 Now $3.12 +47.65% ▲ +12.25% +13.52% vs SPY
  7. Aug 10, 202614w ago 8-K Bearish 7/10 Entry $4.50 to $5.91 Now $3.12 +30.67% ▼ −31.33% −31.38% vs SPY
  8. Aug 6, 202614w ago 8-K Neutral 4/10 Entry $49.61 to $6.54 Now $3.12 −93.71% ▼ −86.82% −88.03% vs SPY
  9. Jul 9, 202618w ago Insider Cluster Neutral 4/10 Entry $45.29 to $45.29 Now $3.12 −93.11% · 0.00% +0.56% vs SPY
  10. Jul 9, 202618w ago Insider Cluster Bearish 5/10 Entry $45.29 to $45.29 Now $3.12 +93.11% · 0.00% −0.56% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 8h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026